Ginsenosides Rb3 and Rc Exhibit Anti-Amoebic Activities Against Naegleria fowleri, the Etiological Agent of Primary

Thu Hằng Nguyễn1,2, Hương Giang Lê1,2, Tuấn Cường Võ1,2

  • 1Department of Parasitology and Tropical Medicine, Institute of Medical Science, Gyeongsang National University College of Medicine, Jinju 52727, Republic of Korea.

Insights

Ginsenosides Rb3 and Rc show promise as novel treatments for primary amoebic meningoencephalitis (PAM). These compounds effectively kill Naegleria fowleri while sparing human cells, inducing programmed cell death in the amoeba.

Area of Science:

  • Pharmacology
  • Parasitology
  • Cell Biology

Background:

  • Primary amoebic meningoencephalitis (PAM) is a fatal neuroinflammatory disease caused by Naegleria fowleri.
  • Current treatment options for PAM are limited, highlighting the need for new therapeutic strategies.
  • Ginsenosides Rb3 and Rc are investigated for their potential anti-amoebic properties.

Purpose of the Study:

  • To evaluate the anti-Naegleria fowleri activity of ginsenosides Rb3 and Rc.
  • To assess the cytotoxicity of Rb3 and Rc against human glial cells.
  • To elucidate the mode of action of Rb3 and Rc against N. fowleri.

Main Methods:

  • Cell viability assays were used to determine anti-amoebic activity and cytotoxicity.
  • Apoptosis, necrosis, reactive oxygen species (ROS) production, and mitochondrial function were analyzed.
  • Caspase-3 activity, ATP production, and autophagy were measured.

Main Results:

  • Ginsenosides Rb3 and Rc demonstrated significant anti-N. fowleri activity with low cytotoxicity to C6 glial cells.
  • Treatment with Rb3 and Rc induced apoptosis-like programmed cell death in N. fowleri.
  • Enhanced ROS production, mitochondrial dysfunction, caspase-3 activation, and autophagy were observed.

Conclusions:

  • Ginsenosides Rb3 and Rc are effective against Naegleria fowleri by inducing programmed cell death.
  • These ginsenosides exhibit selective toxicity, making them potential candidates for PAM therapy.
  • Further research into Rb3 and Rc could lead to novel therapeutic strategies for PAM.